Approach for a Subset of Substances Prioritized during Categorization That Have Already Been Addressed

(PDF Format - 258 KB)

Table of Contents

• 1. Introduction
• 2. Analysis
  • 2.1 Substances from the first Priority Substances List
  • 2.2 Substances from the second Priority Substances List
  • 2.3 Substances listed on Schedule 1
  • 2.4 Other substances
• 3. Conclusion

1. Introduction

As a part of the Chemicals Management Plan (CMP), the Government of Canada announced plans to assess and manage, where appropriate, the potential health and ecological risks associated with approximately 4300 substances under the Canadian Environmental Protection Act, 1999 (CEPA 1999). These substances were identified as priorities for further action during the Categorization exercise that was completed in 2006. The current status of each of these substances is available at the Status of Prioritized Substances List.

This exercise identifies those categorized substances for which risk assessment activities can be considered as having already taken place under CEPA 1999.  This exercise looked at individual substances as well as classes, moieties or groups of substances. As a result, some of the individual substances on the Domestic Substances List (DSL) that have been identified through categorization  fall within the breadth of those previously addressed classes or groups.

Based on the applicability of past assessment activities and risk management actions, 248 substances of the approximately 4300 DSL that were identified as priorities through categorization can be considered to be within the scope of other initiatives under CEPA 1999. As such, it is concluded that these substances do not require further risk assessment at this time.  This approach will enable Environment Canada and Health Canada to focus risk assessment activities on categorized substances that have not yet been addressed.

If new information comes to our attention on these substances as a result of:

• identification of new hazard or exposure information which may impact previous analyses of risk;
• international activities;
• further information gathering
• inclusion in future substances grouping or other assessment initiatives; or
• as may be obtained in support risk management activities including performance evaluation and subsequent changes to risk management;
• additional risk assessment or risk management activities may be undertaken.

2. Analysis

An analysis was undertaken to determine which substances that were previously identified as priorities during categorization are associated with other risk assessment or risk management initiatives under CEPA 1999.  The scope of the analysis included substances that were previously addressed by the first Priority Substances List (PSL), the second PSL, as well as substances on Schedule 1 of CEPA 1999. Substances already being considered as part of other CMP initiatives, such as assessments already planned or underway, rapid screening and the Substance Groupings Initiative were excluded from the scope of the analysis. In addition, substances containing more than one categorized moiety were excluded from the scope of the analysis when at least one of the categorized moieties would be anticipated to be subject to future risk assessment activity.

Where substances are found to have been addressed under past or current risk assessment or risk management activities, it is concluded that no further risk assessment activity is required at this time.

2.1 Substances from the first Priority Substances List

The first Priority Substances List (PSL1) was published in 1989 and included 44 substances or groups of substances. Ecological and human health risk assessments were completed as part of the Priority Substances Assessment Program by early 1994.

2.1.1 Discrete substances

The 46 discrete substances listed in Table 1 are deemed to be within the scope of the PSL1 assessments. As such, these 46 substances do not require further risk assessment at this time.

2.1.2 Moiety-based assessments

For the purpose of this document, “moiety” signifies a part of a molecule which forms the basis of an assessment.

Arsenic

The PSL1 assessment of "Arsenic and its compounds" focused on arsenic and its inorganic compounds.

The 14 inorganic arsenic compounds listed in Table 2 are considered within the scope of the PSL1 assessment of "arsenic and its compounds". As such, these 14 inorganic arsenic substances do not require further risk assessment at this time.

Cadmium

The PSL1 assessment of "Cadmium and its compounds" focused on inorganic cadmium compounds.

The 10 inorganic cadmium compounds listed in Table 3 are considered within the scope of the PSL1 assessment of "cadmium and its compounds". As such, these 10 inorganic cadmium compounds do not require further risk assessment at this time.

Chromium

The PSL1 assessment of “Chromium and it compounds” includes the inorganic form, salts and organometallic species of chromium.

The 62 chromium compounds listed in Table 4 are considered within the scope of the PSL1 assessment of “chromium and it compounds”. As such, these 62 chromium compounds do not require further risk assessment at this time.

Nickel

The PSL1 assessment of "Nickel and its compounds" focused on nickel and inorganic.

The 21 nickel compounds listed in Table 5 are considered within the scope of the PSL1 assessment of “nickel and its compounds”. As such, these 21 nickel compounds do not require further risk assessment at this time.

2.2 Substances from the second Priority Substances List

The second Priority Substances List (PSL2) of the Canadian Environmental Protection Act was published in December, 1995. The list, recommended by a Ministers' Expert Advisory Panel drawn from major stakeholder groups, contained 25 substances, including single chemicals as well as mixtures and effluents.

Eleven substances that were assessed under the second Priority Substances List were also identified as priorities from categorization.

The substances listed in Table 6 are considered within the scope of the PSL2 assessments. As such, these 11 substances do not require further risk assessment at this time.

2.3 Substances listed on Schedule 1

A number of substances prioritized during categorization also appear on the List of Toxic Substances in Schedule 1 of CEPA 1999. As such, these substances do not require further risk assessment at this time.

Chlorobiphenyls

Polychlorinated biphenyls (PCBs) are listed as item 1 of the List of Toxic Substances in Schedule 1 of CEPA 1999. The Government of Canada has already taken action to eliminate PCBs from Canada through a number of domestic Regulatory and voluntary tools to manage the risks associated with these substances

One substance identified as a priority during categorization (CAS RN 1336-36-3, 1,1’-Biphenyl, chloro derivs.) belongs to this group. As such, this substance does not require further risk assessment at this time.

Mercury and its Compounds

“Mercury and its compounds” are listed as item 8 of the List of Toxic Substances in Schedule 1 of CEPA 1999. Environment Canada and Health Canada published a Risk Management Strategy for Mercury (RMS) in October 2010, covering all forms of mercury. The listing on Schedule 1 was modified in 2012, from “Mercury” to “Mercury and its compounds”.

The 26 substances listed in Table 7 are identified as mercury or mercury compounds and are all covered under the Schedule 1 listing. There is also a clear association between these 26 substances, the Schedule 1 listing and the associated risk management actions. As such, these 26 mercury compounds do not require further risk assessment at this time.

Lead

“Lead” is listed as item 7 of the List of Toxic Substances in Schedule 1 of CEPA 1999. Health Canada and Environment Canada published a Final Human Health State of the Science Report on Lead (SOS) and a Risk Management Strategy for Lead (RMS) in February 2013. 

These reports cover exposures to total lead and provide a comprehensive description of the existing management measures and progress to date under the Canadian Federal Risk Management Strategy for Lead. While many of these actions were triggered primarily by human health concerns, they have led to very substantial reductions of releases to the environment (as confirmed by the National Pollutant Release Inventory reporting and by environmental monitoring), thereby reducing potential environmental concerns. Research and monitoring will continue to measure levels of lead in Canadians and, where appropriate, assess the performance of potential control measures identified during the risk management phase. 

As such, these 56 lead compounds do not require further risk assessment at this time.

2.4 Other substances

Lindane

Lindane (CAS RN 58-89-9, Cyclohexane, 1,2,3,4,5,6-hexachloro-, (1a,2a,3ß,4a,5a,6ß)-) has been identified as a remaining priority.

This substance is listed in Part 2 ‘Substances subject to notification and consent’ of Schedule 3 of CEPA 1999.

In 2011 Canada ratified an amendment adding lindane to the Stockholm Convention on Persistent Organic Pollutants. Before considering ratification, Canada assessed the adequacy of domestic risk management measures currently in place for this substance against the obligations under the Stockholm Convention which, once implemented, would require the manufacture, use and import of lindane to be prohibited. The Stockholm Convention also provides Parties with an option of claiming a five-year exemption period, upon ratification, to provide time for the transition to safer alternatives.

To ensure that Canada meets these obligations, the Government of Canada has been working with the two companies in Canada that produced lindane-based pharmaceuticals to phase out the use of lindane and lindane-containing products before the expiry of the exemption period (April 4, 2016), and to ensure that any remaining stockpiles of lindane and products containing lindane are disposed of in an environmentally sound manner. The use of lindane in the production of lindane-containing products by the two companies ceased by January 2011 and February 2012, respectively. The sale of lindane-containing products ceased by May 2011 and December 2012, respectively. The Drug Identification Numbers (DINs) for the lindane-containing products have been cancelled as of March 2013.

As such, it is proposed that lindane does not require further risk assessment at this time.

3. Conclusion

248 substances on the DSL identified as priorities through categorization will not be subject to further risk assessment work at this time under the CMP given past and current risk assessment activities or risk management actions.

Date modified:

2015-02-06